Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| THERMO FISHER SCIENTIFIC INC.TMO · Entity 2836 | Executive Vice President | February 28, 2026 | March 02, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | May 01, 2026 | May 05, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director · President and CEO | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
THERMO FISHER SCIENTIFIC INC.
Report date February 28, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,151.304 |
Ending reported balance
After 2026-02-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-28 · Tax withholding · Disposed 836.88 · Balance 85,511.029 Row 2 · 2026-02-28 · Tax withholding · Disposed 359.725 · Balance 85,151.304 |
VERTEX PHARMACEUTICALS INC / MA
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $424.45 · Expires 2036-04-30 | Direct | 2,866 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 2,866 · Balance 2,866 F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
WEST PHARMACEUTICAL SERVICES INC
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $337.75 · Expires 2036-09-08 | Direct | 13,879 |
Reported balance
After 2026-09-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-08 · Grant · Acquired 13,879 · Balance 13,879 F1: This award vests in four equal annual installments beginning on September 8, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $337.75 · Expires 2036-09-08 | Direct | 11,081 |
Reported balance
After 2026-09-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-08 · Grant · Acquired 11,081 · Balance 11,081 F1: This award vests in four equal annual installments beginning on September 8, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $337.75 · Expires 2036-09-08 | Direct | 12,088 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Grant · Acquired 12,088 · Balance 12,088 F2: This award cliff vests on September 8, 2031. |
| Rst. Stock UnitSEC Table II · derivative / convertible security | Direct | 6,200 |
Reported balance
After 2026-09-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-08 · Grant · Acquired 6,200 · Balance 6,200 F3: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F1: This award vests in four equal annual installments beginning on September 8, 2027. |
| Rst. Stock UnitSEC Table II · derivative / convertible security | Direct | 4,950 |
Reported balance
After 2026-09-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-08 · Grant · Acquired 4,950 · Balance 4,950 F3: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F1: This award vests in four equal annual installments beginning on September 8, 2027. |
| Rst. Stock UnitSEC Table II · derivative / convertible security | Direct | 3,600 |
Reported balance
After 2026-09-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-08 · Grant · Acquired 3,600 · Balance 3,600 F3: Each restricted stock unit represents a contingent right to receive one share of WST common stock. F2: This award cliff vests on September 8, 2031. |
Filing footnotes · ownership attribution and instrument terms
F1: This award vests in four equal annual installments beginning on September 8, 2027.
F2: This award cliff vests on September 8, 2031.
F3: Each restricted stock unit represents a contingent right to receive one share of WST common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Patheon N.V.
Report date August 29, 2017 · Filed August 31, 2017
Section 16 reporting ended · disclosed 2017-08-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-29 transaction · row 1
1 source rowRow 1 · 2017-08-29 · Other · Disposed 245,939 · Balance 0 F1: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2) F2: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3) F3: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer. F4: This amount includes 201,199 unvested restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.49 | Direct | 0 |
Reported balance
After 2017-08-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-08-29 · Disposition to issuer · Disposed 110,402 · Balance 0 F5: The terms of the Option awards provide that options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Options were disposed of pursuant to the Purchase Agreement, whereby each vested option was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (x) the excess of $35.00 over the per Share exercise price of the option, multiplied by the number of Shares subject to the option upon the closing of the tender offer (rounded down to the nearest whole share). Each unvested option was cancelled and converted into a stock option award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested option immediately prior to the closing of the tender offer, (i) with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded down to the nearest whole share) obtained by multiplying (x) (continued in footnote 6) F6: the Exchange Ratio by (y) the total number of Shares subject to such unvested option as of immediately prior to the closing of the tender offer and (ii) at an exercise price per share that is equal to the quotient (rounded up to the nearest cent) obtained by dividing (x) the exercise price per share of such unvested option by (y) the Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2)
F2: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3)
F3: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer.
F4: This amount includes 201,199 unvested restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer.
F5: The terms of the Option awards provide that options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Options were disposed of pursuant to the Purchase Agreement, whereby each vested option was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (x) the excess of $35.00 over the per Share exercise price of the option, multiplied by the number of Shares subject to the option upon the closing of the tender offer (rounded down to the nearest whole share). Each unvested option was cancelled and converted into a stock option award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested option immediately prior to the closing of the tender offer, (i) with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded down to the nearest whole share) obtained by multiplying (x) (continued in footnote 6)
F6: the Exchange Ratio by (y) the total number of Shares subject to such unvested option as of immediately prior to the closing of the tender offer and (ii) at an exercise price per share that is equal to the quotient (rounded up to the nearest cent) obtained by dividing (x) the exercise price per share of such unvested option by (y) the Exchange Ratio.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2020 Filed Mar 5, 2020 21:28 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | SaleCommon Stock | 12,000 | $319.81 | $3,837,720.00 |
DisclosureSEC source: 0001127602-20-009624 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,385.205 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 3, 2020. Read SEC document |
| February 26, 2020 Filed Feb 27, 2020 21:57 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 432 | $309.16 | $133,557.12 |
DisclosureSEC source: 0001127602-20-008158 · form4.xml · nonDerivative · entry 4 Lagarde Michel · CIK 0001518973 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,385.205 Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 21:57 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 18,275 | $0.00 Strike: $309.63 | $0.00 |
DisclosureSEC source: 0001127602-20-008158 · form4.xml · derivative · entry 5 Lagarde Michel · CIK 0001518973 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,275 Underlying: Common Stock · 18,275 shares Expires 2027-02-25 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 25, 2021. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 21:57 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 677 | $309.63 | $209,619.51 |
DisclosureSEC source: 0001127602-20-008158 · form4.xml · nonDerivative · entry 3 Lagarde Michel · CIK 0001518973 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,817.205 Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 21:57 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 6,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-008158 · form4.xml · nonDerivative · entry 2 Lagarde Michel · CIK 0001518973 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,494.205 F1 · shares: Shares represent a performance-based restricted stock unit award granted on February 26, 2019. The Company's Compensation Committee determined on February 25, 2020, that the performance criteria related to this award was satisfied. One-third of the shares vested on February 25, 2020, one-third of the shares vest on February 25, 2021, and the remaining one-third vest on February 25, 2022. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 21:57 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 4,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-008158 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,566.205 Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 20:24 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $294.02 | $0.00 |
DisclosureSEC source: 0001127602-19-028071 · form4.xml · derivative · entry 2 Lagarde Michel · CIK 0001518973 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2026-09-05 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on September 5, 2020. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 20:24 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-028071 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,141.205 Read SEC document |
| August 27, 2019 Filed Aug 29, 2019 20:12 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 245 | $272.93 | $66,867.85 |
DisclosureSEC source: 0001127602-19-027561 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,241.205 Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 20:32 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 283 | $270.92 | $76,670.36 |
DisclosureSEC source: 0001127602-19-027458 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,486.205 Read SEC document |
| July 20, 2019 Filed Jul 23, 2019 20:17 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 7,048 | $293.73 | $2,070,209.04 |
DisclosureSEC source: 0001127602-19-025077 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,769.205 Read SEC document |
| March 23, 2019 Filed Mar 26, 2019 20:25 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 1,258 | $271.05 | $340,980.90 |
DisclosureSEC source: 0001127602-19-013213 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,817.205 Read SEC document |
| March 07, 2019 Filed Mar 11, 2019 20:37 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 789 | $250.81 | $197,889.09 |
DisclosureSEC source: 0001127602-19-010819 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,075.205 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:39 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 18,550 | $0.00 Strike: $253.99 | $0.00 |
DisclosureSEC source: 0001127602-19-008996 · form4.xml · derivative · entry 4 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,550 Underlying: Common Stock · 18,550 shares Expires 2026-02-26 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 26, 2020. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:39 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 376 | $253.99 | $95,500.24 |
DisclosureSEC source: 0001127602-19-008996 · form4.xml · nonDerivative · entry 3 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,864.205 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:39 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008996 · form4.xml · nonDerivative · entry 2 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,240.205 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:39 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 3,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008996 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,990.205 F1 · shares: Shares represent a performance-based restricted stock unit award granted on February 27, 2018. The Company's Compensation Committee determined on February 26, 2019, that the performance criteria related to this award was satisfied. One-third of the shares vested on February 26, 2019, one-third of the shares vest on February 26, 2020, and the remaining one-third vest on February 26, 2021. Read SEC document |
| August 27, 2018 Filed Aug 28, 2018 20:46 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 147 | $237.92 | $34,974.24 |
DisclosureSEC source: 0001127602-18-026398 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,140.205 Read SEC document |
| July 20, 2018 Filed Jul 24, 2018 20:08 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 7,055 | $216.08 | $1,524,444.40 |
DisclosureSEC source: 0001127602-18-023778 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,287.205 Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 20:55 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 882 | $207.33 | $182,865.06 |
DisclosureSEC source: 0001127602-18-012842 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,342.205 Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 20:52 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | Tax withholdingCommon Stock | 314 | $212.16 | $66,618.24 |
DisclosureSEC source: 0001127602-18-010926 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,224.205 Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 21:50 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $210.68 | $0.00 |
DisclosureSEC source: 0001127602-18-009375 · form4.xml · derivative · entry 2 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 7,900 shares Expires 2025-02-27 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 27, 2019. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 21:50 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 2,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-009375 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,538.205 F1 · balance_after: This number reflects a reduction of 98.795 shares which consists of (i) the inadvertent over-declaration of 159 shares in the Form 4 filed on August 31, 2017, and (ii) an aggregate of 60.205 shares that were acquired as dividend equivalents on October 16, 2017 and January 15, 2017. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:32 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 36,500 | $0.00 Strike: $190.59 | $0.00 |
DisclosureSEC source: 0001127602-17-027266 · form4.xml · derivative · entry 2 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,500 Underlying: Common Stock · 36,500 shares Expires 2024-09-07 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on September 7, 2018. Read SEC document |
| September 07, 2017 Filed Sep 11, 2017 20:32 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 7,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-027266 · form4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,437 Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 18:30 UTC | Patheon N.V. PTHN · Entity 173467 | Disposition to issuerOptions (Right to Buy) · Derivative | 110,402 | Not disclosed Strike: $26.49 | Not disclosed |
DisclosureSEC source: 0001209191-17-050950 · doc4.xml · derivative · entry 2 Lagarde Michel · CIK 0001518973 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 110,402 shares Expires not disclosed F5 · price: The terms of the Option awards provide that options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Options were disposed of pursuant to the Purchase Agreement, whereby each vested option was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (x) the excess of $35.00 over the per Share exercise price of the option, multiplied by the number of Shares subject to the option upon the closing of the tender offer (rounded down to the nearest whole share). Each unvested option was cancelled and converted into a stock option award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested option immediately prior to the closing of the tender offer, (i) with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded down to the nearest whole share) obtained by multiplying (x) (continued in footnote 6) F6 · price: the Exchange Ratio by (y) the total number of Shares subject to such unvested option as of immediately prior to the closing of the tender offer and (ii) at an exercise price per share that is equal to the quotient (rounded up to the nearest cent) obtained by dividing (x) the exercise price per share of such unvested option by (y) the Exchange Ratio. F5 · derivative.exercise_date: The terms of the Option awards provide that options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Options were disposed of pursuant to the Purchase Agreement, whereby each vested option was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (x) the excess of $35.00 over the per Share exercise price of the option, multiplied by the number of Shares subject to the option upon the closing of the tender offer (rounded down to the nearest whole share). Each unvested option was cancelled and converted into a stock option award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested option immediately prior to the closing of the tender offer, (i) with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded down to the nearest whole share) obtained by multiplying (x) (continued in footnote 6) F6 · derivative.exercise_date: the Exchange Ratio by (y) the total number of Shares subject to such unvested option as of immediately prior to the closing of the tender offer and (ii) at an exercise price per share that is equal to the quotient (rounded up to the nearest cent) obtained by dividing (x) the exercise price per share of such unvested option by (y) the Exchange Ratio. F5 · derivative.expiration_date: The terms of the Option awards provide that options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Options were disposed of pursuant to the Purchase Agreement, whereby each vested option was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (x) the excess of $35.00 over the per Share exercise price of the option, multiplied by the number of Shares subject to the option upon the closing of the tender offer (rounded down to the nearest whole share). Each unvested option was cancelled and converted into a stock option award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested option immediately prior to the closing of the tender offer, (i) with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded down to the nearest whole share) obtained by multiplying (x) (continued in footnote 6) F6 · derivative.expiration_date: the Exchange Ratio by (y) the total number of Shares subject to such unvested option as of immediately prior to the closing of the tender offer and (ii) at an exercise price per share that is equal to the quotient (rounded up to the nearest cent) obtained by dividing (x) the exercise price per share of such unvested option by (y) the Exchange Ratio. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 18:30 UTC | Patheon N.V. PTHN · Entity 173467 | OtherOrdinary Shares | 245,939 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-050950 · doc4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2) F2 · kind: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3) F3 · kind: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer. F4 · shares: This amount includes 201,199 unvested restricted stock units, each of which represented a contingent right to receive one Share of Issuer. Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. F1 · price: Ordinary shares of Patheon N.V. ("Issuer") were disposed of pursuant to a tender offer by Thermo Fisher (CN) Luxembourg S.a r.l., a private limited liability company (societe a responsabilite limitee) organized under the laws of the Grand Duchy of Luxembourg ("Purchaser") and Thermo Fisher Scientific Inc., a Delaware corporation ("Thermo Fisher"), to acquire all of the issued and outstanding ordinary shares (the "Shares") of Issuer at a purchase price of $35.00 per Share, pursuant to the terms of the Purchase Agreement, dated as of May 15, 2017 (as it may be amended from time to time, the "Purchase Agreement"), by and between Issuer, Purchaser and Thermo Fisher. Pursuant to the terms of the Purchase Agreement, each vested restricted stock unit was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product obtained by multiplying $35.00 by the total number of Shares subject to the restricted stock unit (continued in footnote 2) F2 · price: upon the closing of the tender offer (with restricted stock units that are subject to performance conditions vesting based on achievement of actual performance conditions in accordance with the terms of the award). Each unvested restricted stock unit was cancelled and converted into a restricted stock unit award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such unvested restricted stock unit immediately prior to the closing of the tender offer, with respect to a number of shares of Thermo Fisher common stock equal to the product (rounded to the nearest whole share) obtained by multiplying (x) the Exchange Ratio by (y) the total number of Shares subject to the unvested restricted stock unit as of immediately prior to the closing of the tender offer. (continued in footnote 3) F3 · price: The "Exchange Ratio" is 0.1996919, which represents the quotient obtained by dividing (i) $35.00 by (ii) the average closing price, rounded to the nearest cent, per share of common stock of Thermo Fisher on the NYSE for the consecutive period of ten (10) trading days immediately preceding (but not including) the date of the closing of the tender offer. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 22:35 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 22,046 | Not disclosed Strike: $132.66 | Not disclosed |
DisclosureSEC source: 0001104659-17-054984 · a4.xml · derivative · entry 4 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,046 Underlying: Common Stock · 22,046 shares Expires 2027-03-23 F5 · price: Pursuant to the terms of the Purchase Agreement, upon the Closing, each outstanding and unvested option to acquire Patheon Shares (each, a "Patheon Option") that was unvested as of immediately prior to the Closing was canceled and converted into a stock option award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such Patheon Option as of immediately prior to the Closing, (i) with respect to a number of Thermo Fisher Shares that is equal to (x) 0.1996919 multiplied by (y) the total number of Patheon Shares subject to such Patheon Option as of immediately prior to the Closing (rounded down to the nearest whole share) and (ii) at an exercise price per Thermo Fisher Share that is equal to (x) the exercise price per share of such Patheon Option divided by (y) 0.1996919 (rounded up to the nearest cent). F6 · price: Notwithstanding the foregoing, with respect to the performance-based Patheon Options held by Mr. Lagarde, the performance goals were deemed satisfied as of the Closing and the resulting Thermo Fisher options were subject to the following vesting schedule: 50% of the options were deemed vested as of the Closing and 50% of the options would vest in full on the third anniversary of the Closing, subject to Mr. Lagarde's continued employment with Thermo Fisher (or an earlier qualifying termination of employment). F5 · derivative.exercise_date: Pursuant to the terms of the Purchase Agreement, upon the Closing, each outstanding and unvested option to acquire Patheon Shares (each, a "Patheon Option") that was unvested as of immediately prior to the Closing was canceled and converted into a stock option award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such Patheon Option as of immediately prior to the Closing, (i) with respect to a number of Thermo Fisher Shares that is equal to (x) 0.1996919 multiplied by (y) the total number of Patheon Shares subject to such Patheon Option as of immediately prior to the Closing (rounded down to the nearest whole share) and (ii) at an exercise price per Thermo Fisher Share that is equal to (x) the exercise price per share of such Patheon Option divided by (y) 0.1996919 (rounded up to the nearest cent). F6 · derivative.exercise_date: Notwithstanding the foregoing, with respect to the performance-based Patheon Options held by Mr. Lagarde, the performance goals were deemed satisfied as of the Closing and the resulting Thermo Fisher options were subject to the following vesting schedule: 50% of the options were deemed vested as of the Closing and 50% of the options would vest in full on the third anniversary of the Closing, subject to Mr. Lagarde's continued employment with Thermo Fisher (or an earlier qualifying termination of employment). F8 · derivative.exercise_date: The options are scheduled to vest in three equal installments on each anniversary of the grant date of the original Patheon Option (March 23, 2017). Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 22:35 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantStock Option (Right to Buy) · Derivative | 142,637 | Not disclosed Strike: $105.17 | Not disclosed |
DisclosureSEC source: 0001104659-17-054984 · a4.xml · derivative · entry 3 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,637 Underlying: Common Stock · 142,637 shares Expires 2026-07-20 F5 · price: Pursuant to the terms of the Purchase Agreement, upon the Closing, each outstanding and unvested option to acquire Patheon Shares (each, a "Patheon Option") that was unvested as of immediately prior to the Closing was canceled and converted into a stock option award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such Patheon Option as of immediately prior to the Closing, (i) with respect to a number of Thermo Fisher Shares that is equal to (x) 0.1996919 multiplied by (y) the total number of Patheon Shares subject to such Patheon Option as of immediately prior to the Closing (rounded down to the nearest whole share) and (ii) at an exercise price per Thermo Fisher Share that is equal to (x) the exercise price per share of such Patheon Option divided by (y) 0.1996919 (rounded up to the nearest cent). F6 · price: Notwithstanding the foregoing, with respect to the performance-based Patheon Options held by Mr. Lagarde, the performance goals were deemed satisfied as of the Closing and the resulting Thermo Fisher options were subject to the following vesting schedule: 50% of the options were deemed vested as of the Closing and 50% of the options would vest in full on the third anniversary of the Closing, subject to Mr. Lagarde's continued employment with Thermo Fisher (or an earlier qualifying termination of employment). F5 · derivative.exercise_date: Pursuant to the terms of the Purchase Agreement, upon the Closing, each outstanding and unvested option to acquire Patheon Shares (each, a "Patheon Option") that was unvested as of immediately prior to the Closing was canceled and converted into a stock option award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such Patheon Option as of immediately prior to the Closing, (i) with respect to a number of Thermo Fisher Shares that is equal to (x) 0.1996919 multiplied by (y) the total number of Patheon Shares subject to such Patheon Option as of immediately prior to the Closing (rounded down to the nearest whole share) and (ii) at an exercise price per Thermo Fisher Share that is equal to (x) the exercise price per share of such Patheon Option divided by (y) 0.1996919 (rounded up to the nearest cent). F6 · derivative.exercise_date: Notwithstanding the foregoing, with respect to the performance-based Patheon Options held by Mr. Lagarde, the performance goals were deemed satisfied as of the Closing and the resulting Thermo Fisher options were subject to the following vesting schedule: 50% of the options were deemed vested as of the Closing and 50% of the options would vest in full on the third anniversary of the Closing, subject to Mr. Lagarde's continued employment with Thermo Fisher (or an earlier qualifying termination of employment). F7 · derivative.exercise_date: 50% of the options were deemed vested as of the Closing and 50% of the options are scheduled to vest on the third anniversary of the Closing. Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 22:35 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 8,481 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-054984 · a4.xml · nonDerivative · entry 2 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,337 F1 · price: Pursuant to the terms of the Purchase Agreement, by and between Thermo Fisher Scientific Inc. ("Thermo Fisher"), Patheon N.V. ("Patheon") and Thermo Fisher (CN) Luxembourg S.a r.l., dated as of May 15, 2017 (the "Purchase Agreement"), upon the Closing (as defined in the Purchase Agreement), each outstanding and unvested Patheon restricted stock unit ("RSU") award that was unvested as of immediately prior to the Closing and that was not held by a non-employee director of Patheon was canceled and converted into an RSU award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such Patheon RSU as of immediately prior to the Closing, with respect to the number of shares of common stock of Thermo Fisher ("Thermo Fisher Shares") that is equal to: F2 · price: (x) 0.1996919 multiplied by (y) the total number of ordinary shares of Patheon ("Patheon Shares") subject to such Patheon RSU as of immediately prior to the Offer Closing (rounded to the nearest whole share). Each RSU represents a contingent right to receive one Thermo Fisher Share. F4 · price: The RSUs are scheduled to vest in three equal installments on each anniversary of the grant date of the original Patheon RSU (March 23, 2017). Read SEC document |
| August 29, 2017 Filed Aug 31, 2017 22:35 UTC | THERMO FISHER SCIENTIFIC INC. TMO · Entity 2836 | GrantCommon Stock | 31,856 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-17-054984 · a4.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,856 F1 · price: Pursuant to the terms of the Purchase Agreement, by and between Thermo Fisher Scientific Inc. ("Thermo Fisher"), Patheon N.V. ("Patheon") and Thermo Fisher (CN) Luxembourg S.a r.l., dated as of May 15, 2017 (the "Purchase Agreement"), upon the Closing (as defined in the Purchase Agreement), each outstanding and unvested Patheon restricted stock unit ("RSU") award that was unvested as of immediately prior to the Closing and that was not held by a non-employee director of Patheon was canceled and converted into an RSU award, with substantially the same terms and conditions (including with respect to vesting) as were applicable to such Patheon RSU as of immediately prior to the Closing, with respect to the number of shares of common stock of Thermo Fisher ("Thermo Fisher Shares") that is equal to: F2 · price: (x) 0.1996919 multiplied by (y) the total number of ordinary shares of Patheon ("Patheon Shares") subject to such Patheon RSU as of immediately prior to the Offer Closing (rounded to the nearest whole share). Each RSU represents a contingent right to receive one Thermo Fisher Share. F3 · price: The RSUs are scheduled to vest in two equal installments on July 26, 2018 and July 26, 2019. Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 12:06 UTC | Patheon N.V. PTHN · Entity 173467 | Tax withholdingOrdinary Shares | 34,625 | $34.90 | $1,208,412.50 |
DisclosureSEC source: 0001643848-17-000030 · wf-form4_150091234845749.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,939 Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 15:20 UTC | Patheon N.V. PTHN · Entity 173467 | GrantOptions (Right to Buy) · Derivative | 110,402 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001643848-17-000022 · wf-form4_149064241169300.xml · derivative · entry 2 Lagarde Michel · CIK 0001518973 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,402 Underlying: Options (Right to Buy) · 110,402 shares Expires not disclosed F2 · derivative.exercise_date: The options vest in three equal installments on each anniversary of the grant date of March 23, 2017. F2 · derivative.expiration_date: The options vest in three equal installments on each anniversary of the grant date of March 23, 2017. Read SEC document |
| March 23, 2017 Filed Mar 27, 2017 15:20 UTC | Patheon N.V. PTHN · Entity 173467 | GrantRestricted Stock Units (Ordinary Shares) | 42,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001643848-17-000022 · wf-form4_149064241169300.xml · nonDerivative · entry 1 Lagarde Michel · CIK 0001518973 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,564 F1 · shares: The restricted stock units vest in three equal installments on each anniversary of the grant date of March 23, 2017. Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.